secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001213900-25-073937
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q2 net loss $15M; cash $145.6M into mid-2027; key trial readouts set
----------------------------------------------------------------------------

- Q2 2025 net loss $15.0M ($0.35/shr) vs $9.5M ($0.45/shr) in Q2 2024; R&D spend up to $10.8M.
- Cash, equivalents and investments $145.6M at June 30, expected to fund operations into mid-2027.
- Interim data from ~25 BCG-unresponsive NMIBC patients (ADVANCED-2 trial) expected at 1Q 2026 medical conference.
- First patient in THRIVE-3 Phase 3 registrational trial of IV Choline Chloride on track for 3Q 2025.
- Appointed William Conkling as Chief Commercial Officer in June 2025; added to Russell 3000 Index.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/0001213900-25-073937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/ea0250509-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer